Propanc Biopharma Publishes Key Findings on Pancreatic Cancer Research

Propanc Biopharma announced that the Company and its joint research partners at the Universities of Jaen and Granada published key findings in a peer reviewed journal, Scientific Reports, regarding the impact of proenzymes on pancreatic ductal adenocarcinoma, PDAC, fibroblasts. From the publishers of Nature, Scientific Reports is an online, open access journal, which publishes primary research from all areas of the natural and clinical sciences. The article is entitled, "Impact of pancreatic proenzymes on pancreatic ductal adenocarcinoma associated fibroblasts." PDAC is characterized by a dense fibrotic stroma containing a significant enriched population of cancer-associated fibroblasts. The interplay between CAFs and tumor cells is crucial in driving tumor advancement and metastasis, underscoring the potential benefits of novel therapeutic strategies targeting stromal cells to improve patient survival. PRP, consisting of two bovine derived pancreatic proenzymes, trypsinogen and chymotrypsinogen, have shown efficacy in cancer treatment. The findings demonstrate PRP exerts multifaceted effects. Results underscore the candidacy of PRP as a potential disruptor of the TME.